Welcome to our dedicated page for FIV news (Ticker: FIV), a resource for investors and traders seeking the latest updates and insights on FIV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FIV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FIV's position in the market.
The First Trust Senior Floating Rate 2022 Target Term Fund (NYSE: FIV) has completed its termination and liquidation as of December 15, 2021, following its investment objectives. Initially launched on December 21, 2016, the Fund aimed to return $9.85 per share but fell short, providing a net asset value (NAV) of $9.753232 upon liquidation. Over five years, it distributed $1.6732 per share, achieving an average distribution rate of 3.613%. Shareholders may need to consider tax implications from this liquidation.
The First Trust Senior Floating Rate 2022 Target Term Fund (NYSE: FIV) has announced its liquidation and termination effective December 15, 2021. Common shares are expected to cease trading on the NYSE by December 9, 2021, with final liquidating distributions occurring on the termination date. The fund aims to return $9.85 per share but anticipates a lower return due to market conditions, with a net asset value of $9.71 as of September 13, 2021. Management fees will be waived during the wind-up period, and shareholders may incur tax implications from the liquidation.
